🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

Exclusive-Pfizer explores sale of hospital drugs unit, sources say

Published 11/12/2024, 09:47 AM
Updated 11/12/2024, 10:37 AM
© Reuters. FILE PHOTO: The Pfizer logo is seen at their UK commercial headquarters in Walton Oaks, Britain, February 1, 2021. REUTERS/Matthew Childs/File Photo
US500
-
PFE
-

By Anirban Sen

NEW YORK (Reuters) - Pfizer (NYSE:PFE) is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.

The unit, now called Pfizer Hospital, was formed after Pfizer bought Hospira for about $17 billion in 2015. The pharma giant has hired Goldman Sachs to gauge initial interest from potential buyers, which include private equity firms and other pharmaceutical companies, the sources said, requesting anonymity as the discussions are confidential.

After its takeover of Hospira, Pfizer combined the biosimilars business with its own unit that manufactured lower-cost near copies of expensive biotech drugs. In 2017, Pfizer sold the hospital infusion system business that it had acquired through the takeover. 

The Pfizer Hospital unit is now a subsidiary focused primarily on antibiotics and other drugs delivered as sterile infusions or injectibles in hospitals and clinics. 

The business, which could be worth a few billion dollars, currently generates nearly $500 million of earnings before interest, taxes, depreciation and amortization, the sources said, cautioning that a deal is not guaranteed and Pfizer could choose to keep the division. 

Pfizer and Goldman declined to comment. 

New York-based Pfizer, which held long-term debt of $61.5 billion at the end of 2023, has been shedding non-core businesses and ownership stakes in companies to reduce its debt pile. In October, Pfizer sold a stake worth about $3.26 billion in British consumer healthcare group Haleon. 

The moves come at a time when Pfizer, led by Chief Executive Albert Bourla, is facing pressure from Starboard, which has criticized management for overspending on big acquisitions and failing to produce profitable new drugs from those deals or from its internal research and development. 

Last year, it acquired cancer drugmaker Seagen for $43 billion in what was one of the company's biggest ever deals. 

© Reuters. People walk past the booth of drugmaker Pfizer booth at the China International Import Expo (CIIE) in Shanghai, China November 7, 2024. REUTERS/Andrew Silver/File Photo

Pfizer's shares are down about 7% this year, underperforming the S&P 500, which has risen nearly 26% during the same period. 

On its most recent post-earnings conference call, Pfizer CFO Dave Denton said the company has paid down about $4.4 billion of debt this year and would continue to evaluate non-core assets that could be offloaded.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.